Saira  Ramasastry net worth and biography

Saira Ramasastry Biography and Net Worth

Director of Vir Biotechnology
Saira Ramasastry has served as a member of our board of directors since September 2019. Ms. Ramasastry has served as Managing Partner of Life Sciences Advisory, LLC since April 2009, a company that she founded to provide strategic advice, business development solutions and innovative financing strategies for the life science industry. Ms. Ramasastry also serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research, and as business and sustainability lead for the European Prevention of Alzheimer’s Dementia consortium. From August 1999 to March 2009, Ms. Ramasastry was an investment banker with Merrill Lynch & Co., Inc. where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions, strategic and capital markets transactions. Prior to joining Merrill Lynch she served as a financial analyst in the mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm, from July 1997 to September 1998. Ms. Ramasastry currently serves on the board of directors of the following public companies: Akouos, Inc., DayOne Biopharmaceuticals, Inc., Glenmark Pharmaceuticals, Ltd. and Mirum Pharmaceuticals. Ms. Ramasastry received her B.A. in economics with honors and distinction and an M.S. in management science and engineering from Stanford University, as well as an M. Phil. in management studies from the University of Cambridge where she is a guest lecturer for the Bioscience Enterprise Programme and serves on the Cambridge Judge Business School Advisory Council. Ms. Ramasastry is also a Health Innovator Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network.

What is Saira Ramasastry's net worth?

The estimated net worth of Saira Ramasastry is at least $88,774.84 as of June 1st, 2023. Ms. Ramasastry owns 10,619 shares of Vir Biotechnology stock worth more than $88,775 as of April 16th. This net worth estimate does not reflect any other assets that Ms. Ramasastry may own. Learn More about Saira Ramasastry's net worth.

How do I contact Saira Ramasastry?

The corporate mailing address for Ms. Ramasastry and other Vir Biotechnology executives is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. Vir Biotechnology can also be reached via phone at 415-906-4324 and via email at [email protected]. Learn More on Saira Ramasastry's contact information.

Has Saira Ramasastry been buying or selling shares of Vir Biotechnology?

Saira Ramasastry has not been actively trading shares of Vir Biotechnology during the past quarter. Most recently, Saira Ramasastry sold 3,500 shares of the business's stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $25.67, for a transaction totalling $89,845.00. Following the completion of the sale, the director now directly owns 10,619 shares of the company's stock, valued at $272,589.73. Learn More on Saira Ramasastry's trading history.

Who are Vir Biotechnology's active insiders?

Vir Biotechnology's insider roster includes Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.

Are insiders buying or selling shares of Vir Biotechnology?

In the last twelve months, insiders at the sold shares 30 times. They sold a total of 1,233,926 shares worth more than $29,460,794.79. The most recent insider tranaction occured on April, 3rd when CEO Backer Marianne De sold 72,995 shares worth more than $690,532.70. Insiders at Vir Biotechnology own 18.1% of the company. Learn More about insider trades at Vir Biotechnology.

Information on this page was last updated on 4/3/2024.

Saira Ramasastry Insider Trading History at Vir Biotechnology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/1/2023Sell3,500$25.67$89,845.0010,619View SEC Filing Icon  
7/11/2022Sell5,000$30.00$150,000.008,092View SEC Filing Icon  
5/24/2022Sell1,687$23.82$40,184.348,092View SEC Filing Icon  
See Full Table

Saira Ramasastry Buying and Selling Activity at Vir Biotechnology

This chart shows Saira Ramasastry's buying and selling at Vir Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vir Biotechnology Company Overview

Vir Biotechnology logo
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $8.36
Low: $8.34
High: $8.56

50 Day Range

MA: $10.20
Low: $8.57
High: $11.90

2 Week Range

Now: $8.36
Low: $7.72
High: $27.48

Volume

660,958 shs

Average Volume

1,049,183 shs

Market Capitalization

$1.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.41